Advertisement Pharmaceutical Business review - Page 165 of 5294 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 19, 2026

Estuary secures $103m to advance kidney disease gene therapies

US-based genetic medicines developer Estuary Biotherapeutics has launched after securing $103m in total committed financing for developing targeted gene therapies to treat kidney diseases.

Continue
ADPKD is an inherited, progressive disorder where fluid-filled cysts expand in both kidneys. Credit: sasirin pamai/Shutterstock.com.
October 16, 2026

Acta Pharmaceuticals raises $24m for Alzheimer’s therapies

Researchers will examine the oral small-molecule GSM-779690T ‘s tolerability, pharmacokinetics, and safety. Credit: Gorodenkoff/Shutterstock.com.
October 15, 2026

QCi and INmune Bio partner to study XPro in Alzheimer’s

Researchers will combine INmune Bio’s findings from pre-clinical studies and clinical trials with QCi’s Dirac-3S quantum optimisation machine. Credit: Gorodenkoff / Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. Transcripta Bio, Mayo Clinic join force on ALS therapies
  2. Alentis and PinotBio partner to develop claudin-1 oncology ADCs
  3. Charles River partners with Magellan Stem Cells on cell therapy
  4. Pfizer partners with Enodia Therapeutics in $500m drug deal
  5. China’s NMPA clears Foresee’s Camcevi 42 mg for prostate cancer

PRESS RELEASES

Gerresheimer Reports Slight Revenue Growth in Q1 2026 and a Strong Focus on Free Cash Flow
Gerresheimer Reports Slight Revenue Growth in Q1 2026 and a Strong Focus on Free Cash Flow
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with cartriQ® BioPure
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with cartriQ® BioPure
Pharmaceutical Business Review
SCHOTT Pharma and Nemera Deliver Verified Pen Injector Platform with Sterile Cartridge System
SCHOTT Pharma Invests in Sterile Cartridge Production in Hungary
SCHOTT Pharma Invests in Sterile Cartridge Production in Hungary

Suppliers

Whitepapers

Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography